Robert M Silver1, Katherine Ahrens, Luchin F Wong, Neil J Perkins, Noya Galai, Laurie L Lesher, David Faraggi, Jean Wactawski-Wende, Janet M Townsend, Anne M Lynch, Sunni L Mumford, Lindsey Sjaarda, Enrique F Schisterman. 1. Departments of Obstetrics and Gynecology, University of Utah Health Sciences Center and Intermountain Health Care, Salt Lake City, Utah, and University of Colorado, Aurora, Colorado; the Epidemiology Branch, Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Rockville, Maryland; the Department of Statistics, University of Haifa, Mt. Carmel, Haifa, Israel; the Department of Social and Preventive Medicine, University at Buffalo, Buffalo, New York; the Department of Family, Community and Rural Health, Commonwealth Medical College, Scranton, Pennsylvania.
Abstract
OBJECTIVE: To evaluate the association between low-dose aspirin initiated before conception and the risk of preterm birth. METHODS: This was a secondary analysis of the Effects of Aspirin in Gestation and Reproduction trial. Women with a history of pregnancy loss (original stratum: one loss less than 20 weeks of gestation during the previous year; expanded stratum: one or two losses with no restrictions on timing or gestational age of the losses) were randomized to either daily low-dose aspirin (81 mg, n=615) and folic acid or folic acid alone (placebo; n=613). Preterm birth was compared between groups using intent-to-treat analysis. RESULTS:Preterm birth rates were 4.1% (22/535 low-dose aspirin) and 5.7% (31/543 placebo) (relative risk [RR] 0.72, 95% confidence interval [CI] 0.42-1.23); spontaneous preterm birth rates were 1.1% (6/535 low-dose aspirin) and 2.2% (12/543 placebo) (RR 0.51, 95% CI 0.19-1.34); medically indicated preterm birth rates were 2.6% (14/535 low-dose aspirin) and 2.9% (16/543 placebo) (RR 0.89, 95% CI 0.44-1.80). After restriction to confirmed pregnancies using inverse probability weighting, preterm birth rates were 5.7% and 9.0% (RR 0.63, 95% CI 0.37-1.09) and spontaneous preterm birth rates were 1.4% and 3.2% (RR 0.44, 95% CI 0.17-1.18). In confirmed pregnancies in the original stratum, preterm birth occurred in 3.8% and 9.7% of the low-dose aspirin and placebo groups, respectively (RR 0.39, 95% CI 0.16-0.94). CONCLUSION: Preconception low-dose aspirin was not significantly associated with the overall rate of preterm birth. Although the study was underpowered for this secondary analysis, numeric trends in favor of benefit, particularly in the women with a recent, single early pregnancy loss, warrant further investigation. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, www.clinicaltrials.gov, NCT00467363.
RCT Entities:
OBJECTIVE: To evaluate the association between low-dose aspirin initiated before conception and the risk of preterm birth. METHODS: This was a secondary analysis of the Effects of Aspirin in Gestation and Reproduction trial. Women with a history of pregnancy loss (original stratum: one loss less than 20 weeks of gestation during the previous year; expanded stratum: one or two losses with no restrictions on timing or gestational age of the losses) were randomized to either daily low-dose aspirin (81 mg, n=615) and folic acid or folic acid alone (placebo; n=613). Preterm birth was compared between groups using intent-to-treat analysis. RESULTS:Preterm birth rates were 4.1% (22/535 low-dose aspirin) and 5.7% (31/543 placebo) (relative risk [RR] 0.72, 95% confidence interval [CI] 0.42-1.23); spontaneous preterm birth rates were 1.1% (6/535 low-dose aspirin) and 2.2% (12/543 placebo) (RR 0.51, 95% CI 0.19-1.34); medically indicated preterm birth rates were 2.6% (14/535 low-dose aspirin) and 2.9% (16/543 placebo) (RR 0.89, 95% CI 0.44-1.80). After restriction to confirmed pregnancies using inverse probability weighting, preterm birth rates were 5.7% and 9.0% (RR 0.63, 95% CI 0.37-1.09) and spontaneous preterm birth rates were 1.4% and 3.2% (RR 0.44, 95% CI 0.17-1.18). In confirmed pregnancies in the original stratum, preterm birth occurred in 3.8% and 9.7% of the low-dose aspirin and placebo groups, respectively (RR 0.39, 95% CI 0.16-0.94). CONCLUSION: Preconception low-dose aspirin was not significantly associated with the overall rate of preterm birth. Although the study was underpowered for this secondary analysis, numeric trends in favor of benefit, particularly in the women with a recent, single early pregnancy loss, warrant further investigation. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, www.clinicaltrials.gov, NCT00467363.
Authors: Matthew K Hoffman; Shivaprasad S Goudar; Bhalachandra S Kodkany; Mrityunjay Metgud; Manjunath Somannavar; Jean Okitawutshu; Adrien Lokangaka; Antoinette Tshefu; Carl L Bose; Abigail Mwapule; Musaku Mwenechanya; Elwyn Chomba; Waldemar A Carlo; Javier Chicuy; Lester Figueroa; Ana Garces; Nancy F Krebs; Saleem Jessani; Farnaz Zehra; Sarah Saleem; Robert L Goldenberg; Kunal Kurhe; Prabir Das; Archana Patel; Patricia L Hibberd; Emmah Achieng; Paul Nyongesa; Fabian Esamai; Edward A Liechty; Norman Goco; Jennifer Hemingway-Foday; Janet Moore; Tracy L Nolen; Elizabeth M McClure; Marion Koso-Thomas; Menachem Miodovnik; R Silver; Richard J Derman Journal: Lancet Date: 2020-01-25 Impact factor: 79.321
Authors: Lindsay D Levine; Tiffany L Holland; Keewan Kim; Lindsey A Sjaarda; Sunni L Mumford; Enrique F Schisterman Journal: Can J Physiol Pharmacol Date: 2018-12-18 Impact factor: 2.273
Authors: Katherine L Grantz; Angelo Elmi; Sarah J Pugh; Janet Catov; Lindsey Sjaarda; Paul S Albert Journal: Am J Perinatol Date: 2019-06-02 Impact factor: 1.862
Authors: Matthew T Connell; Lindsey A Sjaarda; Rose G Radin; Daniel Kuhr; Sunni L Mumford; Torie C Plowden; Robert M Silver; Enrique F Schisterman Journal: Semin Reprod Med Date: 2017-10-16 Impact factor: 1.303
Authors: Vanessa L Short; Matthew Hoffman; Mrityunjay Metgud; Avinash Kavi; Shivaprasad S Goudar; Jean Okitawutshu; Antoinette Tshefu; Carl L Bose; Musaku Mwenechanya; Elwyn Chomba; Waldemar A Carlo; Lester Figueroa; Ana Garces; Nancy F Krebs; Saleem Jessani; Sarah Saleem; Robert L Goldenberg; Prabir Kumar Das; Archana Patel; Patricia L Hibberd; Emmah Achieng; Paul Nyongesa; Fabian Esamai; Sherri Bucher; Kayla J Nowak; Norman Goco; Tracy L Nolen; Elizabeth M McClure; Marion Koso-Thomas; Menachem Miodovnik; Richard J Derman Journal: AJOG Glob Rep Date: 2021-01-27
Authors: Laura Visser; Marjon A de Boer; Christianne J M de Groot; Tobias A J Nijman; Marieke A C Hemels; Kitty W M Bloemenkamp; Judith E Bosmans; Marjolein Kok; Judith O van Laar; Marieke Sueters; Hubertina Scheepers; Joris van Drongelen; Maureen T M Franssen; J Marko Sikkema; Hans J J Duvekot; Mireille N Bekker; Joris A M van der Post; Christiana Naaktgeboren; Ben W J Mol; Martijn A Oudijk Journal: BMC Pregnancy Childbirth Date: 2017-07-14 Impact factor: 3.007